Hypogammaglobulinemia
3
Pipeline Programs
3
Companies
5
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
OctapharmaPanzyga, 10% Intravenous Solution
GrifolsXembify
GrifolsIVIG
CSL Behringsubcutaneous immunoglobulin
GrifolsIVIG
Clinical Trials (5)
Total enrollment: 380 patients across 5 trials
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
Start: Dec 2025Est. completion: Dec 2029360 patients
Phase 3Not Yet Recruiting
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Start: Dec 2022Est. completion: Jun 2026
Phase 3Recruiting
Intravenous Immunoglobulin (IVIG) in Lung Transplantation
Start: Jun 2005Est. completion: Aug 2010
Phase 2Completed
Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients
Start: Feb 2018Est. completion: May 201920 patients
N/ACompleted
Post-bypass Prophylactic IVIG in Infants and Neonates
Start: May 2014Est. completion: Jun 2015
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 380 patients
3 companies competing in this space